Expanded access will help bring treatments to patients in certain countries within Central and Eastern Europe, the Mediterranean and EurasiaATHENS,...
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025FLORHAM PARK, N.J. and LONDON...
Ritedose Lab Expansion Ritedose is growing in laboratory and drug development capacity - with the announcement of a $17M in-house...
Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research EGI GES 500 Next-Generation HD-EEG Platform...
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamineGranting of Suitability Petition...
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line...
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet...
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and...
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is...
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit H.E. Dr. Majid...
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor...
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies...
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of...
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading...
TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...